Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus THEELIN.
NORGESTIMATE; ETHINYL ESTRADIOL vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category D/X
Category C
Progestin + Estrogen
Estrogen